EA201991059A1 - МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ - Google Patents

МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ

Info

Publication number
EA201991059A1
EA201991059A1 EA201991059A EA201991059A EA201991059A1 EA 201991059 A1 EA201991059 A1 EA 201991059A1 EA 201991059 A EA201991059 A EA 201991059A EA 201991059 A EA201991059 A EA 201991059A EA 201991059 A1 EA201991059 A1 EA 201991059A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
related methods
mutant ospa
ospa fragments
treating
Prior art date
Application number
EA201991059A
Other languages
English (en)
Inventor
Пер Комстедт
Урбан Лундберг
Андреас Майнке
Маркус Ханнер
Вольфганг Шюлер
Бенджамин Вайзел
Кристоф Райниш
Брижитт Громанн
Роберт Шлегль
Original Assignee
Валнева Аустриа Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Валнева Аустриа Гмбх filed Critical Валнева Аустриа Гмбх
Publication of EA201991059A1 publication Critical patent/EA201991059A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Данное изобретение относится к полипептиду, содержащему мутантный фрагмент внешнего поверхностного белка A (OspA), нуклеиновой кислоте, кодирующей его, фармацевтической композиции (в частности, для применения в виде лекарственного средства в способе лечения или профилактики инфекции Borrelia), содержащей полипептид и/или нуклеиновую кислоту, способу лечения или профилактики инфекции Borrelia и способу иммунизации субъекта.
EA201991059A 2012-07-06 2013-07-08 МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ EA201991059A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261668627P 2012-07-06 2012-07-06
US13/802,991 US8986704B2 (en) 2012-07-06 2013-03-14 Mutant fragments of OspA and methods and uses relating thereto

Publications (1)

Publication Number Publication Date
EA201991059A1 true EA201991059A1 (ru) 2020-01-31

Family

ID=49878705

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201991059A EA201991059A1 (ru) 2012-07-06 2013-07-08 МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ
EA201590162A EA033007B1 (ru) 2012-07-06 2013-07-08 ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ЛИПИДИРОВАННЫЙ ГЕТЕРОДИМЕР МУТАНТНЫХ ФРАГМЕНТОВ OspA, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ЕГО ПРИМЕНЕНИЯ

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201590162A EA033007B1 (ru) 2012-07-06 2013-07-08 ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ЛИПИДИРОВАННЫЙ ГЕТЕРОДИМЕР МУТАНТНЫХ ФРАГМЕНТОВ OspA, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ЕГО ПРИМЕНЕНИЯ

Country Status (24)

Country Link
US (9) US8986704B2 (ru)
EP (3) EP3689372A1 (ru)
JP (1) JP6276258B2 (ru)
KR (2) KR102393038B1 (ru)
CN (2) CN104487084B (ru)
AU (2) AU2013285364B2 (ru)
CA (1) CA2876541C (ru)
CY (1) CY1120772T1 (ru)
DK (1) DK2869839T3 (ru)
EA (2) EA201991059A1 (ru)
ES (2) ES2800873T3 (ru)
HK (4) HK1248244A1 (ru)
HR (1) HRP20181689T1 (ru)
HU (1) HUE041286T2 (ru)
LT (1) LT2869839T (ru)
MX (1) MX364623B (ru)
NZ (2) NZ733026A (ru)
PL (1) PL2869839T3 (ru)
PT (1) PT2869839T (ru)
RS (1) RS57847B1 (ru)
SI (1) SI2869839T1 (ru)
TR (1) TR201815419T4 (ru)
WO (1) WO2014006226A1 (ru)
ZA (1) ZA201409222B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986704B2 (en) * 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
WO2015104396A1 (en) * 2014-01-09 2015-07-16 Valneva Austria Gmbh Mutant fragments of ospa and methods and uses relating thereto
KR102433588B1 (ko) * 2014-06-27 2022-08-19 우베 가부시키가이샤 할로겐 치환 헤테로환 화합물의 염
WO2016022958A2 (en) * 2014-08-07 2016-02-11 The Trustees Of Columbia University In The City Of New York Tick-associated virus sequences and uses thereof
JP6995756B2 (ja) * 2015-12-23 2022-02-04 ノバルティス アーゲー レチノイン酸を含む水中油型エマルジョン
US11345969B2 (en) 2016-02-11 2022-05-31 The Translational Genomics Research Institute Systems and methods for the detection of infectious diseases
WO2018189372A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
KR20190001421U (ko) 2019-05-26 2019-06-13 이준형 노크형 내부 수납식 칫솔
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用
CN111269919B (zh) * 2020-03-19 2021-07-13 四川农业大学 玉米基因ZmLIP2及其应用
WO2021205022A1 (en) 2020-04-09 2021-10-14 Valneva Austria Gmbh Improved methods of producing a lipidated protein
MX2022012647A (es) 2020-04-09 2023-01-16 Valneva Austria Gmbh Composiciones que comprenden tres proteinas de fusion de ospa para uso medico.
CA3230594A1 (en) * 2021-09-02 2023-03-09 Vaxcyte, Inc. Stabilization of adjuvanted vaccine compositions and their use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008625B2 (en) * 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
AU2001285049A1 (en) * 2000-08-18 2002-03-04 Brookhaven Sciences Associates, Llc Altered ospa of borrelia burgdorferi
UA89481C2 (ru) 2003-09-30 2010-02-10 Центокор, Инк. Эритропоэтиновые миметические шарнирно-сердцевинные миметитела человека, композиции, способы и применение
CA2661224A1 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
SI2484375T1 (en) 2006-09-26 2018-08-31 Infectious Disease Research Institute A vaccine composition comprising a synthetic adjuvant
CA2798331C (en) 2010-05-14 2022-03-15 Baxter International Inc. Ospa chimeras and use thereof in vaccines
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
WO2015104396A1 (en) 2014-01-09 2015-07-16 Valneva Austria Gmbh Mutant fragments of ospa and methods and uses relating thereto
CZ2014320A3 (cs) 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
WO2018189372A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto

Also Published As

Publication number Publication date
HUE041286T2 (hu) 2019-05-28
CN104487084B (zh) 2017-09-22
HK1248244A1 (zh) 2018-10-12
US20170101446A1 (en) 2017-04-13
HK1257893A1 (zh) 2019-11-01
LT2869839T (lt) 2018-11-12
EA201590162A1 (ru) 2015-06-30
EP3360568A1 (en) 2018-08-15
US20140010835A1 (en) 2014-01-09
CN104487084A (zh) 2015-04-01
ZA201409222B (en) 2016-08-31
US20220185851A1 (en) 2022-06-16
JP6276258B2 (ja) 2018-02-07
CA2876541C (en) 2022-03-01
HRP20181689T1 (hr) 2018-12-28
CN107602676B (zh) 2021-06-04
TR201815419T4 (tr) 2018-11-21
US8986704B2 (en) 2015-03-24
US20150232517A1 (en) 2015-08-20
US20200239525A1 (en) 2020-07-30
US11208439B2 (en) 2021-12-28
JP2015522270A (ja) 2015-08-06
HK1207982A1 (en) 2016-02-19
US10544194B2 (en) 2020-01-28
KR20200141096A (ko) 2020-12-17
RS57847B1 (sr) 2018-12-31
US20170107263A1 (en) 2017-04-20
ES2800873T3 (es) 2021-01-04
EP2869839A1 (en) 2015-05-13
EP3360568B1 (en) 2020-03-04
CN107602676A (zh) 2018-01-19
AU2017218974A1 (en) 2017-09-07
KR102190981B1 (ko) 2020-12-15
MX364623B (es) 2019-05-03
EA033007B1 (ru) 2019-08-30
ES2688883T3 (es) 2018-11-07
NZ733026A (en) 2019-09-27
MX2015000013A (es) 2015-06-04
AU2013285364A1 (en) 2015-01-29
PL2869839T3 (pl) 2018-12-31
KR20150036191A (ko) 2015-04-07
CA2876541A1 (en) 2014-01-09
DK2869839T3 (en) 2018-10-15
EP3689372A1 (en) 2020-08-05
WO2014006226A1 (en) 2014-01-09
EP2869839B1 (en) 2018-09-05
HK1209370A1 (en) 2016-04-01
CY1120772T1 (el) 2019-12-11
SI2869839T1 (sl) 2018-11-30
AU2017218974B2 (en) 2019-05-30
US9926343B2 (en) 2018-03-27
AU2017218974C1 (en) 2020-02-20
PT2869839T (pt) 2018-11-12
US20150250865A1 (en) 2015-09-10
US11466058B2 (en) 2022-10-11
AU2013285364B2 (en) 2017-06-15
US20230295245A1 (en) 2023-09-21
NZ703597A (en) 2017-06-30
US20180327460A1 (en) 2018-11-15
KR102393038B1 (ko) 2022-04-29

Similar Documents

Publication Publication Date Title
EA201991059A1 (ru) МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ
EA201691095A1 (ru) Мутантные фрагменты ospa и связанные с ними способы и применение
MX2014009909A (es) Acido nucleico que comprende o codifica un tallo-bucle de histona y una secuencia poli(a) o una señal de poliadenilacion para incrementar la expresion de un antigeno tumoral codificado.
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
MD4716B1 (ru) Антитела анти-LAG3 и антигенсвязывающие фрагменты
MX359954B (es) Ácido nucleico que comprende o codifica para un asa troncal de histona y una secuencia poly (a) o una señal de poliadenilación para aumentar la expresión de un antígeno patogénico codificado.
EA201490039A1 (ru) Химерные и гибридные полипептиды фактора viii и способы их применения
CA2818969A1 (en) Improved n-terminal capping modules for designed ankyrin repeat proteins
SG194176A1 (en) Bcma (cd269/tnfrsf17) -binding proteins
EA201491644A1 (ru) Фармацевтические композиции
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
EA201790876A1 (ru) Способ контроля, предотвращения или лечения кровотечения
BR112014028476A2 (pt) fragmento imunogênico de um polipeptídeo, polinucleotídeo isolado, composição farmacêutica imunogênica, métodos para tratar uma infecção, para gerar uma resposta imune em um sujeito, e para imunizar um sujeito
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
EA201690159A1 (ru) Способы и композиции для лечения рака
MX366178B (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
EA201891141A1 (ru) Новые антиангиогенные слитые полипептиды
EA201491513A1 (ru) Рекомбинантные штаммы escherichia coli
RU2015119523A (ru) Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1
MX2011008456A (es) Anticuerpos anti-mst1r y usos de los mismos.
EA201491668A1 (ru) Вакцины и способы для лечения болезни лайма у собак
EA201690766A1 (ru) Растворимый fc-гамма рецептор для лечения аутоиммунных буллезных заболеваний
WO2012158639A3 (en) Recombinant fusion proteins and methods for use thereof for treatment or prevention of papillomavirus infection
CY1116948T1 (el) Παραγοντες προκλησης αποπτωσης για τη θεραπευτικη αντιμετωπιση του καρκινου και των ανοσων και αυτοανοσων ασθενειων